Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

• Skin Diseases
• Infection

• Drug: Tigecycline
  50 mg IV every 12 hours up to 14 days
  Other Name: Tygacil
• Drug: Clindamycin (or Vancomycin if needed)
  For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours

• Experimental: A
  Tigecycline
  Intervention: Drug: Tigecycline
• Active Comparator: B
  Clindamycin (or Vancomycin if needed)
  Intervention: Drug: Clindamycin (or Vancomycin if needed)

Inclusion Criteria:

• Male or female subjects 8 to 17 years old. Children with bone maturation less than 8 years old should be enrolled with caution due to potential risk of tooth discoloration.
• Have a diagnosis of a serious infection requiring hospitalization and administration of IV antibiotic therapy.
• complicated skin and skin structure infections (cSSSI) requiring significant surgical intervention or involving deeper soft tissue with the presence of at least one sign of systemic infection

Exclusion Criteria:

• Subject with any concomitant illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and/or completion of the study, or could preclude the evaluation of the subject's response (e.g., life expectancy < 30 days).